Glucocorticoids Suppress Mitochondrial Oxidant Production via Upregulation of Uncoupling Protein 2 in Hyperglycemic Endothelial Cells
Authors:
Open Access
- 29 April 2016
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (4) , e0154813
Abstract
Diabetic complications are the leading cause of morbidity and mortality in diabetic patients. Elevated blood glucose contributes to the development of endothelial and vascular dysfunction, and, consequently, to diabetic micro- and macrovascular complications, because it increases the mitochondrial proton gradient and mitochondrial oxidant production. Therapeutic approaches designed to counteract glucose-induced mitochondrial reactive oxygen species (ROS) production in the vasculature are expected to show efficacy against all diabetic complications, but direct pharmacological targeting (scavenging) of mitochondrial oxidants remains challenging due to the high reactivity of some of these oxidant species. In a recent study, we have conducted a medium-throughput cell-based screening of a focused library of well-annotated pharmacologically active compounds and identified glucocorticoids as inhibitors of mitochondrial superoxide production in microvascular endothelial cells exposed to elevated extracellular glucose. The goal of the current study was to investigate the mechanism of glucocorticoids' action. Our findings show that glucocorticoids induce the expression of the mitochondrial UCP2 protein and decrease the mitochondrial potential. UCP2 silencing prevents the protective effect of the glucocorticoids on ROS production. UCP2 induction also increases the oxygen consumption and the “proton leak” in microvascular endothelial cells. Furthermore, glutamine supplementation augments the effect of glucocorticoids via further enhancing the expression of UCP2 at the translational level. We conclude that UCP2 induction represents a novel experimental therapeutic intervention in diabetic vascular complications. While direct repurposing of glucocorticoids may not be possible for the therapy of diabetic complications due to their significant side effects that develop during chronic administration, the UCP2 pathway may be therapeutically targetable by other, glucocorticoid-independent pharmacological means.Keywords
Funding Information
- Seventh Framework Programme (BE), People Programme (Marie Curie Actions) (628100)
- Juvenile Diabetes Research Foundation (17-2010-542)
This publication has 100 references indexed in Scilit:
- The influence of high glucose on the aerobic metabolism of endothelial EA.hy926 cellsPflügers Archiv - European Journal of Physiology, 2012
- Cellular bioenergetics is regulated by PARP1 under resting conditions and during oxidative stressBiochemical Pharmacology, 2012
- Mesenchymal Stromal Cells Protect Cancer Cells From ROS-induced Apoptosis and Enhance the Warburg Effect by Secreting STC1Molecular Therapy, 2012
- UCP2 regulates energy metabolism and differentiation potential of human pluripotent stem cellsThe EMBO Journal, 2011
- Glutathionylation Acts as a Control Switch for Uncoupling Proteins UCP2 and UCP3Journal of Biological Chemistry, 2011
- Glucocorticoids Modulate MicroRNA Expression and Processing during Lymphocyte ApoptosisJournal of Biological Chemistry, 2010
- Mitochondrial respiratory chain super-complex I–III in physiology and pathologyBiochimica et Biophysica Acta (BBA) - Bioenergetics, 2010
- Reactive oxygen species, reactive nitrogen species and antioxidants in etiopathogenesis of diabetes mellitus type-2Indian Journal of Clinical Biochemistry, 2009
- Lack of Cytochrome c in Mouse Fibroblasts Disrupts Assembly/Stability of Respiratory Complexes I and IVJournal of Biological Chemistry, 2009
- Effects of Intensive Glucose Lowering in Type 2 DiabetesNew England Journal of Medicine, 2008